- Coloplast awarded AscenDrive Agreement for Ostomy Products with Premier, Inc.
- New informational website around larynx cancer surgery
- Nouveau site internet d’informations sur la chirurgie du cancer du larynx
- Nueva web informative sobre la cirugía del cancer de laringe
- Announcement no. 06/2022 - Coloplast announces the successful issuance of EUR 2.2 billion senior notes under its Euro Medium Term Note programme
- Selskabsmeddelelse nr. 06/2022 - Coloplast offentliggør obligationsudstedelse på EUR 2,2 mia. som led i selskabets Euro Medium Term Note-program
- Announcement no. 05/2022 - Coloplast announces the establishment of its Euro Medium Term Note programme
- Selskabsmeddelelse nr. 05/2022 - Coloplast offentliggør etableringen af selskabets Euro Medium Term Note-program
- Coloplast leverer solidt 2. kvartal med 7% organisk vækst og en overskudsgrad på 31% og justerer forventningerne til den organiske vækst for 2021/22 til 6-7% fra omkring 7%
- Coloplast delivers a solid Q2 with 7% organic growth and a 31% EBIT margin and revises full year organic growth guidance to 6-7% from around 7%
More ▼
Key statistics
As of last trade, Coloplast A/S (CBHD:DUS) traded at 112.10, 14.11% above the 52 week low of 98.24 set on Jun 16, 2022.
52-week range
Markit short selling activity
Open | 113.00 |
---|---|
High | 113.00 |
Low | 110.95 |
Bid | 111.95 |
Offer | 112.05 |
Previous close | 112.10 |
Average volume | 160.40 |
---|---|
Shares outstanding | 198.00m |
Free float | 108.92m |
P/E (TTM) | 37.27 |
Market cap | 164.26bn DKK |
EPS (TTM) | 22.26 DKK |
Annual div (ADY) | 2.56 EUR |
---|---|
Annual div yield (ADY) | 2.28% |
Div ex-date | May 09 2022 |
Div pay-date | May 11 2022 |
Data delayed at least 15 minutes, as of Aug 08 2022 10:01 BST.
More ▼